Cilag raises €37.8M Series B round
9 December 2013· Schaffhausen, Switzerland· pharmaceuticals, manufacturing, biotech, b2b, software_hardware
To support the clinical development of the company's lead FynomAb COVA322.
Investors
LeadGimv
Also participating
Novartis Venture FundAscent Biomedical VenturesEdmond de Rothschild Investment Partners
About Cilag
Stage
Series B
Headquarters
Schaffhausen, Switzerland
Founded
1936
Team Size
500+
Sectors
pharmaceuticalsmanufacturingbiotechb2bsoftware_hardware